Xiangxue Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiangxue Ma has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Xudong Tang
Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
5 shared publications - Fengyun Wang
Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese, Medical Sciences, China
4 shared publications - Jinke Huang
Department of Gastroenterology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China
3 shared publications - Jinxin Ma
Department of Gastroenterology, Peking University Traditional Chinese Medicine Clinical Medical School (Xiyuan), Beijing, China
2 shared publications - Mengxiong Lu
Department of Gastroenterology
2 shared publications - Yijun Zheng
Department of Gastroenterology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 14 May 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Stiffness-dependent CMOT hydrogels promote mucosal repair in ulcerative colitis through YAP‑mediated mechanosensing in intestinal epithelial cells
In this study, a series of mechanically tunable CMOT hydrogels was successfully developed, which enable colon‑targeted delivery and controlled degradation via dynamic Schiff‑base cross‑linking. Among them, the moderately stiff CMOT‑M hydrogel best mimics the native mechanical microenvironment of intestinal tissue, significantly alleviating DSS‑induced colitis symptoms, restoring the expression of tight‑junction proteins (ZO‑1, occludin), and suppressing excessive production of inflammatory cytokines (TNF‑α, IL‑6, IL‑1β). Mechanistic investigations revealed that the CMOT‑M hydrogel modulates the Hippo signaling pathway through integrin‑cytoskeletal tension transmission, thereby precisely tuning the phosphorylation status and nuclear translocation of YAP/TAZ: during the acute phase, it moderately activates YAP/TAZ to promote epithelial proliferation and migration; during the repair phase, it suppresses excessive YAP/TAZ activation, guiding stem‑cell differentiation and preventing fibrosis. After loading with the herbal formula QCXPY (CMOT@QCXPY), the hydrogel further synergistically inhibits the IL‑6/STAT3 pathway and reshapes the gut microbiota, establishing a multidimensional regulatory network integrating mechanical, immune, and microbial cues. This work demonstrates that material stiffness serves as a critical design parameter that can promote mucosal regeneration through YAP‑mediated mechanosensing, offering a novel mechano‑therapeutic strategy for ulcerative colitis.
- 14 May 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessStiffness-dependent CMOT hydrogels promote mucosal repair in ulcerative colitis through YAP‑mediated mechanosensing in intestinal epithelial cells
In this study, a series of mechanically tunable CMOT hydrogels was successfully developed, which enable colon‑targeted delivery and controlled degradation via dynamic Schiff‑base cross‑linking. Among them, the moderately stiff CMOT‑M hydrogel best mimics the native mechanical microenvironment of intestinal tissue, significantly alleviating DSS‑induced colitis symptoms, restoring the expression of tight‑junction proteins (ZO‑1, occludin), and suppressing excessive production of inflammatory cytokines (TNF‑α, IL‑6, IL‑1β). Mechanistic investigations revealed that the CMOT‑M hydrogel modulates the Hippo signaling pathway through integrin‑cytoskeletal tension transmission, thereby precisely tuning the phosphorylation status and nuclear translocation of YAP/TAZ: during the acute phase, it moderately activates YAP/TAZ to promote epithelial proliferation and migration; during the repair phase, it suppresses excessive YAP/TAZ activation, guiding stem‑cell differentiation and preventing fibrosis. After loading with the herbal formula QCXPY (CMOT@QCXPY), the hydrogel further synergistically inhibits the IL‑6/STAT3 pathway and reshapes the gut microbiota, establishing a multidimensional regulatory network integrating mechanical, immune, and microbial cues. This work demonstrates that material stiffness serves as a critical design parameter that can promote mucosal regeneration through YAP‑mediated mechanosensing, offering a novel mechano‑therapeutic strategy for ulcerative colitis.
- Open Access
Comprehensive bibliometric and visualized analysis of research on gut-liver axis published from 1998 to 2022
- Open Access
- 31 January 2024
- Published by Wiley in Journal of Food Quality
- Vol. 2024, 1-12
Uncovering the Multitarget Therapeutic Mechanism of Tong-Xie-Yao-Fang on Irritable Bowel Syndrome
Background. This study investigated the pharmacological mechanisms of Tong-Xie-Yao-Fang (TXYF) against irritable bowel syndrome (IBS). Methods. The chemical profile of TXYF was identified through UHPLC-QTOF-MS. Next, the obtained chemical profile served as the basis for network pharmacological analysis. Finally, the predictive performance of network pharmacology was validated by conducting molecular docking and animal experiment. Results. Seven key compounds of TXYF, namely, quercetin, ellagic acid, nobiletin, formononetin, isorhamnetin, vestitol, and licochalcone, were confirmed as the key components acting on IBS. TXYF treatment on IBS was mainly realized through the regulation of some key pathways of immune system, such as inflammatory bowel disease, cytokine-cytokine receptor interaction, HIF-1, and T cell receptor signaling pathway. NOS2, ACHE, ESR1, PTGS2, and RELA were the target genes of TXYF to improve IBS. Stable bonds between the key components and the core target genes were further verified by the results of molecular docking. In vivo experiments confirmed the effects of TXYF on IBS. Further Western blot analysis showed that NOS2, ACHE, and ERα were significantly upregulated in the model group in comparison with controls ( ) but then significantly downregulated after treatment with TXYF for 14 days ( ). Conclusion. This study applied an integrated method based on network pharmacology and experimental validation to examine the underlying “multicomponent, multitarget, and multipathway” mode of action of TXYF in treating IBS. The current findings provided indicative paradigms and new insights into exploring the multitarget therapeutic mechanism of Chinese herbal compound.
- 31 January 2024
- Published by Wiley in Journal of Food Quality
- Vol. 2024, 1-12
Open AccessUncovering the Multitarget Therapeutic Mechanism of Tong-Xie-Yao-Fang on Irritable Bowel Syndrome
Background. This study investigated the pharmacological mechanisms of Tong-Xie-Yao-Fang (TXYF) against irritable bowel syndrome (IBS). Methods. The chemical profile of TXYF was identified through UHPLC-QTOF-MS. Next, the obtained chemical profile served as the basis for network pharmacological analysis. Finally, the predictive performance of network pharmacology was validated by conducting molecular docking and animal experiment. Results. Seven key compounds of TXYF, namely, quercetin, ellagic acid, nobiletin, formononetin, isorhamnetin, vestitol, and licochalcone, were confirmed as the key components acting on IBS. TXYF treatment on IBS was mainly realized through the regulation of some key pathways of immune system, such as inflammatory bowel disease, cytokine-cytokine receptor interaction, HIF-1, and T cell receptor signaling pathway. NOS2, ACHE, ESR1, PTGS2, and RELA were the target genes of TXYF to improve IBS. Stable bonds between the key components and the core target genes were further verified by the results of molecular docking. In vivo experiments confirmed the effects of TXYF on IBS. Further Western blot analysis showed that NOS2, ACHE, and ERα were significantly upregulated in the model group in comparison with controls ( ) but then significantly downregulated after treatment with TXYF for 14 days ( ). Conclusion. This study applied an integrated method based on network pharmacology and experimental validation to examine the underlying “multicomponent, multitarget, and multipathway” mode of action of TXYF in treating IBS. The current findings provided indicative paradigms and new insights into exploring the multitarget therapeutic mechanism of Chinese herbal compound.
- Open Access
- 21 December 2021
- Published by Wiley in Gastroenterology Research and Practice
- Vol. 2021, 1-15
Exploration of the Potential Mechanisms of Wumei Pill for the Treatment of Ulcerative Colitis by Network Pharmacology
Background. Wumei pill (WMP) has a long history of colitis treatment in China, but the protective mechanisms have not been elucidated. To uncover the potential mechanisms of WMP against ulcerative colitis (UC), the network pharmacology approach was utilized in this study. Methods. Public databases were utilized to identify the potential targets of WMP and genes related to UC. Based on the identified overlapping common targets, drug-ingredient-target gene network, Gene Ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, and protein-protein interaction (PPI) analysis were conducted. Molecular docking was carried out to verify the selected key active ingredients and core targets. Results. 129 active ingredients and 622 target genes were obtained. The drug-ingredient-target gene network revealed 52 active ingredients of WMP acting on 73 targets related to UC. GO analysis revealed that biological processes were mainly associated with oxidative stress, such as, reactive oxygen species metabolic processes, response to oxidative stress, cellular response to oxidative stress, response to reactive oxygen species, and regulation of reactive oxygen species metabolic processes. KEGG analysis revealed that the immune- and inflammation-related pathways, tumor-related signaling pathways, and microbial infection-related signaling pathways were the most significant. PPI network identified 13 core target genes. The molecular docking results indicated the formation of stable bonds between the active ingredients and core target genes. Conclusions. The approach of network pharmacology reveals the key ingredients, potential core targets, and biological process of WMP in the treatment of UC. The mechanisms of action of WMP involve anti-inflammation, antioxidation, and modulation of immunity, which provides evidence for the therapeutic role of WMP in UC.
- 21 December 2021
- Published by Wiley in Gastroenterology Research and Practice
- Vol. 2021, 1-15
Open AccessExploration of the Potential Mechanisms of Wumei Pill for the Treatment of Ulcerative Colitis by Network Pharmacology
Background. Wumei pill (WMP) has a long history of colitis treatment in China, but the protective mechanisms have not been elucidated. To uncover the potential mechanisms of WMP against ulcerative colitis (UC), the network pharmacology approach was utilized in this study. Methods. Public databases were utilized to identify the potential targets of WMP and genes related to UC. Based on the identified overlapping common targets, drug-ingredient-target gene network, Gene Ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, and protein-protein interaction (PPI) analysis were conducted. Molecular docking was carried out to verify the selected key active ingredients and core targets. Results. 129 active ingredients and 622 target genes were obtained. The drug-ingredient-target gene network revealed 52 active ingredients of WMP acting on 73 targets related to UC. GO analysis revealed that biological processes were mainly associated with oxidative stress, such as, reactive oxygen species metabolic processes, response to oxidative stress, cellular response to oxidative stress, response to reactive oxygen species, and regulation of reactive oxygen species metabolic processes. KEGG analysis revealed that the immune- and inflammation-related pathways, tumor-related signaling pathways, and microbial infection-related signaling pathways were the most significant. PPI network identified 13 core target genes. The molecular docking results indicated the formation of stable bonds between the active ingredients and core target genes. Conclusions. The approach of network pharmacology reveals the key ingredients, potential core targets, and biological process of WMP in the treatment of UC. The mechanisms of action of WMP involve anti-inflammation, antioxidation, and modulation of immunity, which provides evidence for the therapeutic role of WMP in UC.
- Open Access
- 15 December 2021
- Published by Wiley in Pain Research and Management
- Vol. 2021, 1-10
Quality of Evidence Supporting the Role of Acupuncture for the Treatment of Irritable Bowel Syndrome
Objectives. To systematically collate, appraise, and synthesize the current evidence on acupuncture for irritable bowel syndrome (IBS). Methods. Systematic reviews (SRs)/meta-analyses (MAs) of acupuncture for IBS were searched in eight databases. For quality evaluation of the enrolled studies, Assessment of Multiple Systematic Reviews 2 (AMSTAR-2) was used for methodological quality, Preferred Reporting Item for Systematic Reviews and Meta-Analyses (PRISMA) for reporting quality, and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) for evidence quality. Results. Ten studies were included in our review. According to AMSTAR-2, only one study met all the criteria and was rated as high methodological quality, and the rest were rated as low or very low methodological quality. According to the PRISMA checklist, most of the items were fully reported, with the exception of Q5 (protocol and registration), Q8 (search), and Q27 (funding). With the GRADE system, no outcome measure was rated as high quality. Conclusions. Acupuncture may be a promising therapy for IBS. However, this conclusion must be treated with caution since the quality of SRs/MAs providing evidence is generally low.
- 15 December 2021
- Published by Wiley in Pain Research and Management
- Vol. 2021, 1-10
Open AccessQuality of Evidence Supporting the Role of Acupuncture for the Treatment of Irritable Bowel Syndrome
Objectives. To systematically collate, appraise, and synthesize the current evidence on acupuncture for irritable bowel syndrome (IBS). Methods. Systematic reviews (SRs)/meta-analyses (MAs) of acupuncture for IBS were searched in eight databases. For quality evaluation of the enrolled studies, Assessment of Multiple Systematic Reviews 2 (AMSTAR-2) was used for methodological quality, Preferred Reporting Item for Systematic Reviews and Meta-Analyses (PRISMA) for reporting quality, and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) for evidence quality. Results. Ten studies were included in our review. According to AMSTAR-2, only one study met all the criteria and was rated as high methodological quality, and the rest were rated as low or very low methodological quality. According to the PRISMA checklist, most of the items were fully reported, with the exception of Q5 (protocol and registration), Q8 (search), and Q27 (funding). With the GRADE system, no outcome measure was rated as high quality. Conclusions. Acupuncture may be a promising therapy for IBS. However, this conclusion must be treated with caution since the quality of SRs/MAs providing evidence is generally low.
- Open Access
- 1 January 2017
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2017 (1) , 9086034
The Effect of Tong‐Xie‐Yao‐Fang on Intestinal Mucosal Mast Cells in Postinfectious Irritable Bowel Syndrome Rats
Objective. To investigate the effects of Tong‐Xie‐Yao‐Fang (TXYF) on intestinal mucosal mast cells in rats with postinfectious irritable bowel syndrome (PI‐IBS). Design. PI‐IBS rat models were established using a multistimulation paradigm. Then, rats were treated with TXYF intragastrically at doses of 2.5, 5.0, and 10.0 g·kg−1·d−1 for 14 days, respectively. Intestinal sensitivity was assessed based on abdominal withdrawal reflex (AWR) scores and fecal water content (FWC). Mast cell counts and the immunofluorescence of tryptase and c‐Fos in intestinal mucosa were measured; and serum IL‐1β, TNF‐α, and histamine levels were determined. Results. AWR reactivity and FWC which were significantly increased could be observed in PI‐IBS rats. Remarkably increased mast cell activation ratio in intestinal mucosa, together with increased serum TNF‐α and histamine levels, could also be seen in PI‐IBS rats; furthermore, PI‐IBS‐induced changes in mast cell activation and level of serum TNF‐α and histamine could be reversed by TXYF treatment. Meanwhile, tryptase and c‐Fos expression were also downregulated. Conclusion. TXYF improves PI‐IBS symptoms by alleviating behavioral hyperalgesia and antidiarrhea, the underlying mechanism of which involves the inhibitory effects of TXYF on activating mucosal mast cells, downregulating tryptase and c‐Fos expression, and reducing serum TNF‐α and histamine levels.
- 1 January 2017
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2017 (1) , 9086034
Open AccessThe Effect of Tong‐Xie‐Yao‐Fang on Intestinal Mucosal Mast Cells in Postinfectious Irritable Bowel Syndrome Rats
Objective. To investigate the effects of Tong‐Xie‐Yao‐Fang (TXYF) on intestinal mucosal mast cells in rats with postinfectious irritable bowel syndrome (PI‐IBS). Design. PI‐IBS rat models were established using a multistimulation paradigm. Then, rats were treated with TXYF intragastrically at doses of 2.5, 5.0, and 10.0 g·kg−1·d−1 for 14 days, respectively. Intestinal sensitivity was assessed based on abdominal withdrawal reflex (AWR) scores and fecal water content (FWC). Mast cell counts and the immunofluorescence of tryptase and c‐Fos in intestinal mucosa were measured; and serum IL‐1β, TNF‐α, and histamine levels were determined. Results. AWR reactivity and FWC which were significantly increased could be observed in PI‐IBS rats. Remarkably increased mast cell activation ratio in intestinal mucosa, together with increased serum TNF‐α and histamine levels, could also be seen in PI‐IBS rats; furthermore, PI‐IBS‐induced changes in mast cell activation and level of serum TNF‐α and histamine could be reversed by TXYF treatment. Meanwhile, tryptase and c‐Fos expression were also downregulated. Conclusion. TXYF improves PI‐IBS symptoms by alleviating behavioral hyperalgesia and antidiarrhea, the underlying mechanism of which involves the inhibitory effects of TXYF on activating mucosal mast cells, downregulating tryptase and c‐Fos expression, and reducing serum TNF‐α and histamine levels.